118 related articles for article (PubMed ID: 22450844)
1. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.
Mani J; Vallo S; Barth K; Makarević J; Juengel E; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):250-5. PubMed ID: 22450844
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
3. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
4. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
6. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
[TBL] [Abstract][Full Text] [Related]
7. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
Asbagh LA; Uzunoglu S; Cal C
Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
[TBL] [Abstract][Full Text] [Related]
9. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
Ebert R; Zeck S; Meissner-Weigl J; Klotz B; Rachner TD; Benad P; Klein-Hitpass L; Rudert M; Hofbauer LC; Jakob F
Bone; 2012 Mar; 50(3):723-32. PubMed ID: 22166808
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
11. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
[TBL] [Abstract][Full Text] [Related]
12. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
13. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.
Ullen A; Schwarz S; Lennartsson L; Kalkner KM; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S
Scand J Urol Nephrol; 2009; 43(2):98-103. PubMed ID: 19101859
[TBL] [Abstract][Full Text] [Related]
15. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells.
Tenta R; Sourla A; Lembessis P; Luu-The V; Koutsilieris M
Horm Metab Res; 2005 Oct; 37(10):593-601. PubMed ID: 16278781
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA
Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.
Coxon JP; Oades GM; Kirby RS; Colston KW
BJU Int; 2004 Jul; 94(1):164-70. PubMed ID: 15217454
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
19. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.
Tenta R; Tiblalexi D; Sotiriou E; Lembessis P; Manoussakis M; Koutsilieris M
Prostate; 2004 May; 59(2):120-31. PubMed ID: 15042612
[TBL] [Abstract][Full Text] [Related]
20. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro].
Zhang H; Lü JJ; Gao QZ; Zhang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):382-5. PubMed ID: 16638347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
